ArticleMedComm2025
Tissue Kallikrein as a Mediator in Stroke Outcomes among Patients With Metabolic Syndrome: A Multicenter Study Integrating Big Data and Biomarkers.
Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- High-specificity identification of large vessel occlusion stroke using D-dimer and NT-proBNP combined with clinical variables.Frontiers in neurologyArticle
- Neutrophil-to-albumin ratio as a predictor of sepsis-associated encephalopathy in patients with rheumatoid arthritis: an exploratory machine learning study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) poses a significant risk to the cerebrovascular system, impacting the prognosis of stroke patients. This study investigated the link between MetS and stroke-related outcomes, exploring tissue kallikrein 1 (KLK1) as a potential mediator. In the derivation cohort, a total of 17,106 stroke-diagnosed patients were assessed, with 6917 individuals (40.4%) presenting comorbid MetS. Multifactorial analysis identified stroke concurrent with MetS (adjusted odds ratio = 1.42; 95% confidence interval: 1.17-1.72;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.